Incannex Prospectus
An offer of one option for no additional consideration (Placement Option) for every one Placement Share to be issued to… Read more
An offer of one option for no additional consideration (Placement Option) for every one Placement Share to be issued to… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to attach the address of the CEO,… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic… Read more
Highlights: • Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the… Read more
IHL announce that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year… Read more
Melbourne, Australia, October 28, 2022 – Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or… Read more
For the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27… Read more
Incannex has today announced the completion of dosing of trial participants in a phase 1 clinical trial for arthritis using… Read more